Get the Stockscreener App
9.51
3.94%
-0.39
After Hours:
9.51
Immunome Inc stock is traded at $9.51, with a volume of 684.06K.
It is down -3.94% in the last 24 hours and down -10.28% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$9.90
Open:
$9.89
24h Volume:
684.06K
Relative Volume:
0.80
Market Cap:
$827.80M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-2.8716
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
-7.67%
1M Performance:
-10.28%
6M Performance:
+6.97%
1Y Performance:
-37.60%
1-Day Range:
$9.41
$9.99
1-Week Range:
$9.41
$10.52
52-Week Range:
$5.1501
$16.73
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
9.51 | 861.75M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Regression analysis insights on Immunome Inc. performanceJuly 2025 PreEarnings & Long-Term Investment Growth Plans - Newser
What Fibonacci levels say about Immunome Inc. rebound2025 Retail Activity & Safe Entry Point Alerts - Newser
Is Immunome Inc. trending in predictive chart modelsMarket Growth Review & Fast Exit and Entry Trade Guides - Newser
Using data filters to optimize entry into Immunome Inc.2025 Analyst Calls & Fast Entry High Yield Stock Tips - Newser
Price momentum metrics for Immunome Inc. explainedTrade Analysis Report & Proven Capital Preservation Methods - Newser
Immunome Inc.’s volatility index tracking explainedMarket Activity Report & Target Return Focused Stock Picks - Newser
Will Immunome Inc. continue its uptrendEarnings Risk Summary & Weekly Top Gainers Alerts - Newser
Using Bollinger Bands to evaluate Immunome Inc.Volume Spike & Weekly Breakout Watchlists - Newser
Analyzing net buyer seller activity in Immunome Inc.Weekly Trade Review & Free Technical Confirmation Trade Alerts - Newser
Short interest data insights for Immunome Inc.Trade Volume Report & Reliable Volume Spike Trade Alerts - Newser
Why Immunome Inc. stock attracts strong analyst attentionQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - Newser
Is Immunome Inc. building a consolidation baseQuarterly Trade Report & AI Driven Stock Movement Reports - Newser
Will Immunome Inc. stock recover after recent dropWeekly Risk Summary & Daily Price Action Insights - Newser
Does Immunome Inc. qualify in momentum factor screening2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Best data tools to analyze Immunome Inc. stockWeekly Trade Report & Capital Efficient Trading Techniques - Newser
Is Immunome Inc. a candidate for recovery playEarnings Miss & Risk Managed Trade Strategies - Newser
Will Immunome Inc. bounce back from current supportWeekly Stock Report & High Accuracy Swing Trade Signals - Newser
Analyzing recovery setups for Immunome Inc. investorsStop Loss & Daily Chart Pattern Signal Reports - Newser
Will breakout in Immunome Inc. lead to full recoveryJuly 2025 WrapUp & Weekly Watchlist of Top Performers - Newser
How to build a dashboard for Immunome Inc. stockMarket Risk Summary & Reliable Intraday Trade Alerts - Newser
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):